| Firm | Analyst |
| H.C. Wainwright | Raghuram Selvaraju, PhD |
| Lucid Capital Markets | Elemir Piros, PhD |
| Maxim Group | Michael Okunewitch |
| Paradigm Capital | Scott McAuley, PhD |
| Raymond James | Michael Freeman |
| Research Capital | Andre Uddin |
| Stifel GMP | Justin Keywood |
| TD Cowen | Joe Thome, PhD |
Firms listed in alphabetical order.
NervGen Pharma Corp. is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding NervGen Pharma Corp.’s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of NervGen Pharma Corp. or its management. NervGen Pharma Corp. does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.
NervGen Pharma Corp (“NervGen”) (NASDAQ: NGEN), is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. NervGen’s lead therapeutic candidate, NVG-291, is a first- and potentially best-in-class subcutaneously administered candidate being evaluated in the Phase 1b/2a CONNECT SCI Study in individuals living with spinal cord injury. Through NVG-291 and the Company’s next-generation candidate, NVG-300, NervGen is pursuing a pharmacologic approach to transform the treatment paradigm for neurotraumatic and neurologic conditions with significant unmet medical need.
Contact
112-970 Burrard Street
Unit 1290
Vancouver, BC V6Z 2R4
Phone: (778) 731-1711
Email: info@nervgen.com